- Home
- NGNE vs SFST Comparison
NGNE vs SFST Comparison
Compare NGNE & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- SFST
- Stock Information
- Founded
- NGNE 2003
- SFST 1999
- Country
- NGNE United States
- SFST United States
- Employees
- NGNE N/A
- SFST N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- SFST Major Banks
- Sector
- NGNE Health Care
- SFST Finance
- Exchange
- NGNE Nasdaq
- SFST Nasdaq
- Market Cap
- NGNE 325.3M
- SFST 285.9M
- IPO Year
- NGNE N/A
- SFST 1999
- Fundamental
- Price
- NGNE $22.72
- SFST $44.37
- Analyst Decision
- NGNE Strong Buy
- SFST Buy
- Analyst Count
- NGNE 7
- SFST 1
- Target Price
- NGNE $41.86
- SFST $51.00
- AVG Volume (30 Days)
- NGNE 216.3K
- SFST 27.1K
- Earning Date
- NGNE 08-08-2025
- SFST 07-22-2025
- Dividend Yield
- NGNE N/A
- SFST N/A
- EPS Growth
- NGNE N/A
- SFST 58.49
- EPS
- NGNE N/A
- SFST 2.69
- Revenue
- NGNE $925,000.00
- SFST $102,879,000.00
- Revenue This Year
- NGNE N/A
- SFST $6.08
- Revenue Next Year
- NGNE N/A
- SFST $13.23
- P/E Ratio
- NGNE N/A
- SFST $16.48
- Revenue Growth
- NGNE N/A
- SFST 15.60
- 52 Week Low
- NGNE $6.88
- SFST $29.14
- 52 Week High
- NGNE $74.49
- SFST $45.96
- Technical
- Relative Strength Index (RSI)
- NGNE 60.64
- SFST 73.13
- Support Level
- NGNE $20.80
- SFST $39.03
- Resistance Level
- NGNE $23.88
- SFST $45.96
- Average True Range (ATR)
- NGNE 1.44
- SFST 1.09
- MACD
- NGNE 0.09
- SFST 0.50
- Stochastic Oscillator
- NGNE 72.83
- SFST 78.80
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.